Pfizer's PATINA trial highlights IBRANCE's potential in HR+/HER2+ metastatic breast cancer, improving outcomes with a ...
A significant overall survival (OS) benefit with belantamab mafodotin (belantamab; Blenrep) in a phase III trial of relapsed ...
Imlunestrant, an investigational next-generation selective estrogen receptor degrader (SERD), improved progression-free ...
The researchers found that administering 75 grams of vitamin C three times a week doubled overall survival rates of patients ...
Pfizer, facing increasing pressure from Novartis, is touting a Phase III win for Ibrance as the first clinical evidence ...
Findings seen in patients with microsatellite-instability-high or mismatch-repair-deficient metastatic colorectal cancer ...
Patients with heavily pretreated microsatellite stable metastatic colorectal cancer (CRC) had survival benefits after using ...
Late-breaking research reveals there is no benefit from high-dose chemotherapy followed by autologous stem cell transplant ...
AstraZeneca and Merck report Lynparza's significant survival benefits in high-risk breast cancer and Keytruda combo results ...
For patients with microsatellite-instability-high (MSI-H) or mismatch-repair-deficient (dMMR) metastatic colorectal cancer ...
IN8bio, Inc., a clinical-stage biopharmaceutical company focusing on innovative gamma-delta T cell therapies, recently shared updated data on December 10, 2024. This data demonstrated sustained ...
Johnson & Johnson (JNJ) announced data highlighting that DARZALEX FASPRO (daratumumab and hyaluronidase-fihj)-based regimens improve ...